11:03 AM EDT, 03/31/2026 (MT Newswires) -- Visionary (GV) said Tuesday it entered an agreement with Qingdao Xihai Rongke Enterprise Operation Management related to a proposed $20 million strategic investment for the company's anti-aging project in Qingdao West Coast New Area, China.

Under the deal, the companies will form a project company to serve as the operating entity for the collaboration. The entity will establish the GV China Anti-Aging Research Center in Qingdao, with an initial focus on research and development in areas including cell therapy and biologics, the company said.

The project company will also start creating out a GV Anti-Aging Health Management Center chain model in China, with plans to introduce globally aligned products and service standards, according to a statement.

The investor will inject at least $20 million into the project company across two phases.

The initial phase is structured around three milestone-based payments, with 30% due after establishment of the project company and opening of its capital account, 40% on completion of renovation of the research center and installation of equipment, and the final 30% after the first flagship center opens and generates its first month of operating data.

The second-phase investment of $10 million is contemplated, subject to development progress, according to the company.

Price: 0.34, Change: +0.12, Percent Change: +50.68